Targeting HIF-2: Myth or Reality? A First-In-Class HIF-2 Antagonist for the Treatment of clear cell Renal Cell Carcinoma: PT2385

John A. Josey, Ph.D. Peloton Therapeutics, Inc. presents “Targeting HIF-2: Myth or Reality? A First-In-Class HIF-2 Antagonist for the Treatment of clear cell Renal Cell Carcinoma: PT2385” at the 14th International Kidney Cancer Symposium.

Targeting HIF-2: Myth or Reality? A First-In-Class HIF-2 Antagonist for the Treatment of clear cell Renal Cell Carcinoma: PT2385

Advancing Acute Lymphoblastic Leukemia Treatment with CAR-T Cells: Insights from Dr. Anjali Advani

Advances in Acute Lymphoblastic Leukemia (ALL) Treatment: A Focus on Targeted Therapies – Elias Jabbour, MD

FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

Targeting HIF-2: Myth or Reality? A First-In-Class HIF-2 Antagonist for the Treatment of clear cell Renal Cell Carcinoma: PT2385

Related Posts

Advancing Acute Lymphoblastic Leukemia Treatment with CAR-T Cells: Insights from Dr. Anjali Advani

Advances in Acute Lymphoblastic Leukemia (ALL) Treatment: A Focus on Targeted Therapies – Elias Jabbour, MD

FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia